1,4-Diazepan-2,5-dione Synthesis via Preliminary Electron Withdrawing Group Introduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack a practical production process for 1,4-diazepan-2,5-dione derivatives with an electron withdrawing group at the 4-position nitrogen atom, and there is no reported chymase inhibitory activity in existing compounds similar to those described.
Innovation Solution
A method involving the conversion of a compound with a specific formula, followed by a coupling reaction and subsequent removal of a protective group, to produce a 1,4-diazepan-2,5-dione derivative with chymase inhibitory activity, utilizing electron withdrawing groups like carbonyl or sulfonyl groups.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional lactamization methods are used to produce 1,4-diazepan-2,5-dione derivatives, then the basic skeleton can be formed, but it is impossible to introduce an electron withdrawing group at the 4-position nitrogen atom
Solution Approach 1:
The electron withdrawing group is introduced at the 4-position nitrogen atom before the ring closure reaction. By performing this substitution reaction in advance on the starting material (compound of formula 1), the desired structural feature is established before the diazepan ring is formed, thereby achieving both the correct skeleton and the electron withdrawing group at the critical 4-position.
Solution Approach 2:
The synthesis is divided into distinct sequential steps: first substituting the electron withdrawing group at the nitrogen atom, then performing the ring closure to form the diazepan structure. This segmentation allows each transformation to be optimized independently, ensuring both the structural precision of the final product and the versatility of being able to introduce different electron withdrawing groups.
2Reliability
If existing production methods are used, then similar 1,4-diazepan-2,5-dione skeletons can be obtained, but chymase inhibitory activity is not achieved
Solution Approach 1:
The invention introduces an electron withdrawing group (such as carbonyl, sulfonyl, or cyano groups) at the specific 4-position nitrogen atom of the 1,4-diazepan-2,5-dione ring. This localized structural modification at a specific position on the molecule creates the necessary electronic environment for chymase inhibitory activity, while maintaining the overall reliability of the diazepan skeleton structure.
3Ease of manufacture
If no electron withdrawing group is introduced at the 4-position nitrogen atom, then the production process is simpler, but the compound lacks chymase inhibitory activity
Solution Approach 1:
The electron withdrawing group is introduced in advance during the starting material preparation stage, using standard substitution reactions with reagents such as acyl chlorides, sulfonyl chlorides, or cyanating agents. This preliminary action integrates the bioactive feature into the synthesis route without requiring complex post-synthesis modifications, thereby maintaining process simplicity while ensuring biological activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a practical production of 1,4-diazepan-2,5-dione derivatives with chymase inhibitory activity, useful for treating various diseases, and efficiently produces compounds with high yield.
Implementation Method 1
a 7-membered ring closure reaction using lactamization etc. are reported
Data Source
AI summary
A 7-membered heterocyclic compound having the formula (I), or its salt, or a solvate thereof with a chymase inhibitory action and useful for the prevention or treatment of various diseases, in which chymase is involved: a method for producing the same, and a pharmaceutical composition useful for the prevention or treatment of diseases, in which chymase is involved, including the compound of having the formula (I), or its pharmaceutically acceptable salt, or a solvate thereof are provided.